This study will evaluate the impact of water consumption on the pharmacokinetics of ALKS 5461.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Sublingual tablet administered followed by consumption of 240 mL (8 ounces) of water at different timepoints
Alkermes Investigational Site
Overland Park, Kansas, United States
AUCinf
Area under the plasma concentration-time curve from time 0 to infinity for ALKS 5461
Time frame: Up to 72 hours
AUClast
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration for ALKS 5461
Time frame: Up to 72 hours
Cmax
Maximum observed plasma concentration for ALKS 5461
Time frame: Up to 72 hours
Safety and tolerability will be measured by the incidence of Adverse Effects
Time frame: Up to 46 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.